Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tumor-associated fibroblasts are key regulators of tumorigenesis. In contrast to tumor cells, which are genetically unstable and mutate frequently, the presence of genetically more stable fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer immunotherapy. These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies. To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma. Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma. Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs. Most importantly, pFap-vaccinated mice treated with chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of tumor growth, with 50% of the animals completely rejecting a tumor cell challenge. This strategy opens a new venue for the combination of immuno- and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, depleting fibroblast activation protein (FAP)+ CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Stromal Effects on Mammary Gland Development and Breast Cancer
Wiseman, B. S., & Werb, Z. (2002) · Science · doi:10.1126/science.1067431 · Cited by 923
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Cited by
Items 201–300 of 648
Ohshio, Y., Teramoto, K., Hanaoka, J., Tezuka, N., Itoh, Y., Asai, T., Daigo, Y., & Ogasawara, K. (2015) · Cancer Science · doi:10.1111/cas.12584 · Cited by 92
Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 92
Guo, J. X., Zeng, H., & Chen, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00014 · Cited by 100
The expansion of targetable biomarkers for CAR T cell therapy
Townsend, M. H., Shrestha, G., Robison, R. A., & O'Neill, K. L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0817-0 · Cited by 98
“inhibiting tumor growth and increasing cytotoxicity [247, 255, 256].”
Denys, H. G., Derycke, L., Hendrix, A., Westbroek, W., Gheldof, A., Narine, K., Pauwels, P., Gespach, C. P., Bracke, M., & Wever, O. D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.068 · Cited by 98
“More importantly FAP emerges as a promising candidate for specifically targeting cancer-associated fibroblasts [29].”
BackgroundHIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk
Wang, Y., Weng, X., Wang, L., Hao, M., Li, Y., Hou, L., Liang, Y., Wu, T., Yao, M., Lin, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99974 · Cited by 95
“Notably, Hic1 mice were found to have markedly activated fibroblasts in their mammary gland stroma compared with Hic1 mice based on an evaluation of the expression of α-smooth muscle actin (α-SMA), which is frequently used as a classical marker of CAF in solid tumors (8, 28) (Figure 2A).”
Cell communication networks in cancer invasion
Calvo, F., & Sahai, E. A. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.04.010 · Cited by 101
Adipose tissue-derived progenitor cells and cancer
Zhang, Y. (2010) · World Journal of Stem Cells · doi:10.4252/wjsc.v2.i5.103 · Cited by 87
Roadblocks to translational advances on metastasis research
Brabletz, T., Lyden, D. C., Steeg, P. S., & Werb, Z. (2013) · Nature Medicine · doi:10.1038/nm.3327 · Cited by 93
Qiao, A., Gu, F., Guo, X., Zhang, X., & Fu, L. (2016) · Frontiers of Medicine · doi:10.1007/s11684-016-0431-5 · Cited by 95
Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression
Cammarota, F., & Laukkanen, M. O. (2015) · Stem Cells International · doi:10.1155/2016/4824573 · Cited by 95
“Mechanistically the vaccination sensitizes fibroblasts to CD8 T-cell attack, which leads to decreased collagen production and the significantly increased uptake of chemotherapeutic drugs [119].”
Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures
Sun, Y. (2015) · Medicinal Research Reviews · doi:10.1002/med.21338 · Cited by 83
Effects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
Bagley (2009) · International Journal of Oncology · doi:10.3892/ijo_00000187 · Cited by 89
Kilvaer, T. K., Rakaee, M., Hellevik, T., Al‐Saad, S., Paulsen, E., Bremnes, R. M., Busund, L., Dønnem, T., & Martinez, I. Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134965 · Cited by 89
Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
Liu, M., Song, W., & Huang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.032 · Cited by 85
Estrogen-mediated activation of fibroblasts and its effects on the fibroid cell proliferation
Luo, N., Guan, Q., Zheng, L., Qu, X. A., Dai, H., & Cheng, Z. (2013) · Translational research · doi:10.1016/j.trsl.2013.11.008 · Cited by 87
Hasani‐Sadrabadi, M. M., Taranejoo, S., Dashtimoghadam, E., Bahlakeh, G., Majedi, F. S., VanDersarl, J. J., Janmaleki, M., Sharifi, F., Bertsch, A., Hourigan, K., et al. (2016) · Advanced Materials · doi:10.1002/adma.201502697 · Cited by 83
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
Caramelo, B., Zagorac, S., Corral, S., Marqués, M., & Real, F. X. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.02.011 · Cited by 87
Xiang, R., Luo, Y., Niethammer, A. G., & Reisfeld, R. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00613.x · Cited by 80
“As far as the latter is concerned, we recently found that the efficacy of tumor chemotherapy could be markedly improved by specifically killing TAFs in the TME with a specific DNA-based vaccine, because these cells are major producers of collagen type 1 which correlated inversely with drug uptake by tumor cells (52).”
BackgroundThe application of the fibroblast activation protein α-targeted immunotherapy strategy
Jiang, G., Xu, W., Du, J., Zhang, K.-S., Zhang, Q.-G., Wang, X.-W., Liu, Z.-G., Liu, S., Xie, W., Liu, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8098 · Cited by 86
“Nonspecific immune responses were unlikely, because the cytotoxic effects mediated by CD8+ T cells in vitro were restricted to target cells overexpressing the FAP α antigen, consistent with other studies [59, 60].”
BackgroundResultCancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 86
“Hyalurone, which is produced by CAF, has shown its improved resistance to breast cancer cells.81 Reduction in the uptake of chemotherapeutic drugs in case of breast and colon cancer has been shown by type I collagen, a product of CAF.82 Some studies have also shown increased cancer metastasis and drug resistance by CA…”
BackgroundInfluentialIdentifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 97
“Comparatively, CAFs are genetically more stable and less prone to acquire drug resistance [104].”
BackgroundWhat is new in cancer-associated fibroblast biomarkers?
Zhao, Z., Li, T., Yuan, Y., & Zhu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01125-0 · Cited by 89
“FAP-targeting immunotherapies such as DNA vaccination [29] and chimeric antigen receptor (CAR) T cells [30, 31].”
BackgroundKabir, T. D., Leigh, R. J., Tasena, H., Mellone, M., Coletta, R. D., Parkinson, E. K., Prime, S. S., Thomas, G. J., Paterson, I. C., Zhou, D., et al. (2016) · Aging · doi:10.18632/aging.100987 · Cited by 78
“Elucidating the mechanisms responsible for generating the SASP could have translational benefits since stromal fibroblasts are generally believed to be genetically stable [15] and therefore less vulnerable to developing resistance to therapy, a significant problem with the pharmacological targeting of genetically unst…”
BackgroundCancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Raaijmakers, K., Adema, G. J., Bussink, J., & Ansems, M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03251-0 · Cited by 88
Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma
Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y.-X., Kranz, D. M., Rowley, D. A., & Schreiber, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5324 · Cited by 73
“protein by fibroblasts (42), or legumain by macrophages (43)] as targets for therapy.”
BackgroundWatanabe, S., Noma, K., Ohara, T., Kashima, H., Sato, H., Kato, T., Urano, S., Katsube, R., Hashimoto, Y., Tazawa, H., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1617566 · Cited by 87
Cancer-associated fibroblasts in digestive tumors
Huang, L., Xu, A.-M., Liu, S., Liu, W., & Li, T.-J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17804 · Cited by 75
Cancer stem cells in human gastrointestinal cancer
Taniguchi, H., Moriya, C., Igarashi, H., Saitoh, A., Yamamoto, H., Adachi, Y., & Imai, K. (2016) · Cancer Science · doi:10.1111/cas.13069 · Cited by 85
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
Scott, E. M., Duffy, M. R., Freedman, J. D., Fisher, K. D., & Seymour, L. W. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700187 · Cited by 80
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Andrea, A. E., Chiron, A., Mallah, S., Bessoles, S., Sarrabayrouse, G., & Hacein‐Bey‐Abina, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830292 · Cited by 77
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
Sun, X., Mao, Y., Wang, J., Zu, L., Hao, M., Cheng, G., Qu, Q., Cui, D., Keller, E. T., Chen, X., et al. (2014) · Oncogene · doi:10.1038/onc.2014.158 · Cited by 75
RetractedRBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia
Shields, D. J., Niessen, S., Murphy, E. A., Mielgo, A., Desgrosellier, J. S., Lau, S. K. M., Barnes, L. A., Lesperance, J., Bouvet, M., Tarin, D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911646107 · Cited by 78
Gunderson, A. J., Yamazaki, T., McCarty, K., Phillips, M., Alice, A., Bambina, S., Zebertavage, L., Friedman, D., Cottam, B., Newell, P., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211117 · Cited by 70
Liang, C., Chao, Y., Yi, X., Xu, J., Feng, L., Zhao, Q., Yang, K., & Liu, Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.033 · Cited by 75
Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
Andre, F., Berrada, N., & Desmedt, C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833fb384 · Cited by 64
Kim, D. J., Dunleavey, J. M., Xiao, L., Ollila, D. W., Troester, M. A., Otey, C. A., Li, W., Barker, T. H., & Dudley, A. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0072-3 · Cited by 77
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S., & Fletcher, A. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001203 · Cited by 67
“For example, elimination of FAP CAFs by DNA vaccines enhanced CD8 T cell–mediated elimination of CAFs in murine models of colon and breast cancers (116).”
BackgroundCollagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis
Huang, Y., Liang, C.-Y., Ritz, D., Coelho, R., Septiadi, D., Estermann, M., Cumin, C., Rimmer, N., Schötzau, A., López, M. N., et al. (2020) · eLife · doi:10.7554/elife.59442 · Cited by 80
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
Zhao, Z., Li, T., Sun, L. L., Yuan, Y., & Zhu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115425 · Cited by 76
Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets
Lappano, R., Rigiracciolo, D. C., Belfiore, A., Maggiolini, M., & Francesco, E. M. D. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1751819 · Cited by 71
“expression of collagen type I together with an increased intratumoral uptake of chemotherapeutic drugs [106].”
BackgroundInfluentialBreast tumor stroma: A driving force in the development of resistance to therapies
Majidinia, M., & Yousefi, B. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12893 · Cited by 68
Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles
Vincent, K. M., Findlay, S. D., & Postovit, L.-M. M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0613-0 · Cited by 69
Zhang, Y., Jiang, X., Zhang, N., Chen, M., Wang, H., & Zhu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.017 · Cited by 91
Hintz, H. M., Gallant, J. P., Griend, D. J. V., Coleman, I. M., Nelson, P. S., & LeBeau, A. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1358 · Cited by 71
“Finally, combination therapies that target both CAFs and cancer cells are shown to have a synergistic effect (43, 44).”
BackgroundDrug delivery strategy in hepatocellular carcinoma therapy
Yang, S., Cai, C., Wang, H., Ma, X., Shao, A., Sheng, J., & Yu, C. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00796-x · Cited by 70
“CAFs generate collagen, fibrin, and other components of the ECM, together forming a thick matrix that supports and protects the tumor tissue, preventing drugs from reaching the tumor sites either physically or by altering signaling pathways in the physiology of tumor cells [40, 41].”
BackgroundYu, S., Wang, S., Wang, X., & Xu, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03518-8 · Cited by 79
“FAP-targeting DNA vaccines are prominent among these, with the first orally administered DNA vaccine proving successful in inhibiting primary tumor growth and metastasis in mice by mediating the killing of tumor-associated fibroblasts through CD8 + T cells [308].”
BackgroundBreast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome
Chen, S.-T., Pan, T., Juan, H., Chen, T., Lin, Y.-S., & Huang, C. (2008) · Journal of Proteome Research · doi:10.1021/pr700745n · Cited by 75
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 68
Evaluation of Nanoparticle Uptake in Co-culture Cancer Models
Costa, E. C., Gaspar, V. M., Marques, J. G., Coutinho, P., & Correia, I. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070072 · Cited by 60
“Fibroblasts also secrete and interact with several growth factors [25,29], like hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF) and epithelial growth factor (EGF), that are responsible for the activation of mechanisms that contribute to apoptosis resistance [30,31], and…”
BackgroundEck, S. M., Blackburn, J. S., Schmucker, A. C., Burrage, P. S., & Brinckerhoff, C. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.011 · Cited by 72
“Since stromal cells are recognized as critical contributors cancer pathogenesis, and since these cells are more genetically stable than the tumor cells and are less likely to develop drug resistance, they have been suggested as appropriate therapeutic targets [52,53].”
BackgroundJohann, P.-D., Vaegler, M., Gieseke, F., Mang, P., Armeanu-Ebinger, S., Kluba, T., Handgretinger, R., & Müller, I. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-501 · Cited by 64
“Although the last years have seen a surge in publications highlighting the immunological impact of tumour-microenvironment, additional studies focusing on functional aspects of native human TStrC are sparse [ 24-26 ].”
BackgroundChen, M., Xiang, R., Wen, Y., Xu, G., Wang, C., Luo, S., Yin, T., Wei, X., Shao, B., Liu, N., et al. (2015) · Scientific Reports · doi:10.1038/srep14421 · Cited by 63
Juillerat‐Jeanneret, L., Tafelmeyer, P., & Golshayan, D. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1370455 · Cited by 71
“Ac ce pte d M an us cri pt 15 both cancer and stromal cells; in other murine models of lung and colon carcinoma FAP-α inhibition slowed the growth of the tumors; FAP-α expression was also shown to improve the uptake of chemotherapeutics in multiresistant cancers [137-139].”
Adaptive response of resistant cancer cells to chemotherapy
Chern, Y., & Tai, I. T. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0005 · Cited by 77
Das, S., Valton, J., Duchateau, P. N., & Poirot, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172681 · Cited by 69
Azreq, M.-A. E., Naci, D., & Aoudjit, F. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-02-0132 · Cited by 70
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment
Poggi, A., & Giuliani, M. (2016) · Vaccines · doi:10.3390/vaccines4040041 · Cited by 62
“Interestingly, the FAP expressed on MSC has also been considered as a target for chimeric antigen receptor (CAR) T cells [137,146,147] or redirected T cells [169] (Figure 4).”
BackgroundBahrami, A., Hassanian, S. M., Khazaei, M., Hasanzadeh, M., Shahidsales, S., Maftouh, M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26183 · Cited by 68
An evolving paradigm of cancer stem cell hierarchies: therapeutic implications
Cole, A. J., Fayomi, A. P., Anyaeche, V. I., Bai, S., & Buckanovich, R. J. (2020) · Theranostics · doi:10.7150/thno.41647 · Cited by 69
“Pre-clinical data demonstrated that FAPα vaccines were able to suppresses tumor growth and metastasis in colon and breast cancer models (198,199).”
BackgroundLee, Y. E., Go, G.-Y., Koh, E.-Y., Yoon, H.-N., Seo, M., Hong, S.-M., Jeong, J. H., Kim, J.-C., Cho, D., Kim, T. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006130 · Cited by 61
Mezawa, Y., & Orimo, A. (2021) · FEBS Journal · doi:10.1111/febs.15851 · Cited by 61
CAF-immune cell crosstalk and its impact in immunotherapy
Maia, A. R. R., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00977-x · Cited by 63
“While depletion of FAP+ CAFs from the tumour stroma led to tumour regression and improved survival in mouse models of breast and colon cancers [30, 31], targeting αSMA+ fibroblasts or the sonic hedgehog (Shh) signalling in CAFs to reduce the fibrotic tissue around the tumour, also known as desmoplasia, resulted in acc…”
BackgroundMicroenvironment Cell Contribution to Lymphoma Immunity
Kumar, D., & Xu, M. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00288 · Cited by 66
Dzobo, K. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0019 · Cited by 63
“…using chimeric antigen receptor T cell targeting fibroblast activation protein (FAP)-positive CAFs has demonstrated that CAFs are definitely involved in tumor growth and therapy resistance (Chung et al., 2014; Kakarla et al., 2013; Loeffler et al., 2006; Roberts et al., 2013; Zalc-man et al., 2016).”
Qattan, A. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238905 · Cited by 60
“Cancer-associated fibroblasts (CAFs) secrete extracellular matrix proteins and factors that can block drug delivery to tumor cells [56] and increase resistance in cancer stem cells through STAT/Notch signaling stimulated by fibroblast exosomal RNA [57].”
BackgroundCancer-Associated Fibroblasts: Implications for Cancer Therapy
Maia, A. R. R., & Wiemann, S. (2021) · Cancers · doi:10.3390/cancers13143526 · Cited by 64
Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment
Giorello, M. B., Borzone, F. R., Labovsky, V., Piccioni, F., & Chasseing, N. A. (2021) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-020-09475-y · Cited by 60
Gottschalk, S. M., Feng, Y., Ji, M., Kakarla, S., & Song, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082658 · Cited by 61
“In addition, FAP-targeted vaccines reduced tumor collagen content and modulated the tumor immune microenvironment in preclinical models [13,14].”
BackgroundDocetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
Harris, A. R., Perez, M. J., & Munson, J. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4619-8 · Cited by 60
The role of tumor microenvironment on cancer stem cell fate in solid tumors
Razi, S., Haghparast, A., Khameneh, S. C., Sadrabadi, A. E., Aziziyan, F., Bakhtiyari, M., Nabi‐Afjadi, M., Tarhriz, V., Jalili, A., & Zalpoor, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01129-w · Cited by 59
Dynamic Interactions Between Cancer Stem Cells and Their Stromal Partners
Park, T. S., Donnenberg, V. S., Donnenberg, A. D., Zambidis, E. T., & Zimmerlin, L. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-013-0036-5 · Cited by 55
Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin
Tiago, M., de Oliveira, E. M., Brohem, C. A., Pennacchi, P. C., Paes, R. D., Haga, R. B., Campa, A., de Moraes Barros, S. B., Smalley, K. S., & Maria-Engler, S. S. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0473 · Cited by 55
“Both intrinsic and acquired resistance results from the numerous genetic and epigenetic changes occurring in cancer cells.(5) Furthermore, metastatic melanoma cells are highly plastic and can accommodate new and reorganized microenvironments, consisting of a rich milieu of stromal cells and extracellular molecules.”
Fight the Cancer, Hit the CAF!
Papait, A., Romoli, J., Stefani, F. R., Chiodelli, P., Montresor, M. C., Agoni, L., Silini, A. R., & Parolini, O. (2022) · Cancers · doi:10.3390/cancers14153570 · Cited by 61
Fibroblasts as Turned Agents in Cancer Progression
Wieder, R. (2023) · Cancers · doi:10.3390/cancers15072014 · Cited by 58
Zhang, W., Liu, Q., Wu, J., Xu, B., Wang, J., Liang, L., Guo, Y., Peng, M., Zhao, Y., & Liao, Q. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.164 · Cited by 56
“FAPα is expressed in the extracellular matrix of epithelialderived malignant tumors, embryonic developmental tissue, and wound healing, but not in normal adult tissues (11-13).”
BackgroundTargeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 57
A collagen‐binding EGFR single‐chain Fv antibody fragment for the targeted cancer therapy
Liang, H., Li, X., Chen, B., Wang, B., Zhao, Y., Zhuang, Y., Shen, H., Zhang, Z., & Dai, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.029 · Cited by 54
Shintani, Y., Kimura, T., Funaki, S., Ose, N., Kanou, T., & Fukui, E. (2023) · Cancers · doi:10.3390/cancers15020335 · Cited by 57
“A DNA vaccine directed against FAP suppressed tumor proliferation by stimulating a CD8+ T-cellmediated immune response [100].”
BackgroundTumor–stromal cell interactions and opportunities for therapeutic intervention
Udagawa, T., & Wood, M. L. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.010 · Cited by 57
Chen, Q., He, G., Zhang, W., Xu, T., Qi, H., Li, J., Zhang, Y., & Gao, M. (2016) · Scientific Reports · doi:10.1038/srep27462 · Cited by 59
Stromal contributions to the carcinogenic process
Spaw, M., Anant, S., & Thomas, S. M. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22583 · Cited by 51
“Neuronal cells NT3 and NT4 targeted therapies; GDNF inhibitors; anti-NGF antibodies; anti-PTN antibodies and N-syndecan inhibitors; BDNF inhibitors [99,105,109,111]”
BackgroundQian, B., Yan, F., Li, N., Liu, Q., Lin, Y.-H., Liu, C., Luo, Y., Guo, F., & Li, H. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0997-3 · Cited by 53
“Cancer vaccines in combination with chemotherapy have previously been documented [ 37 ].”
ResultTheranostic Probes for Targeting Tumor Microenvironment: An Overview
Sikkandhar, M., Nedumaran, A., Ravichandar, R., Singh, S., Santhakumar, I., Goh, Z., Mishra, S., Archunan, G., Gulyás, B., & Padmanabhan, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051036 · Cited by 54
“FAP has a unique post-prolyl endopeptidase activity to cleave the dipeptide at the NH2-terminal [96,97].”
BackgroundFang, Y., Xiao, X., Wang, J., Dasari, S., Pépin, D., Nephew, K. P., Zamarin, D., & Mitra, A. K. (2024) · npj Precision Oncology · doi:10.1038/s41698-023-00495-5 · Cited by 58
“CAFs also reduce CSCs uptake of therapeutic drugs by increasing the interstitial fl uid pressure 19 .”
Gong, P., Wang, F., Hua, Y., Ying, J., Chen, J., & Qiao, Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03815-y · Cited by 65
Rong, G., Kang, H., Wang, Y., Hai, T., & Sun, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070960 · Cited by 48
“Furthermore, an oral DNA vaccine targeting fibroblasts activation protein (FAP) was developed to suppress primary tumor cell growth and metastasis of multidrug-resistant murine breast carcinoma and allowed reversing resistance to chemotherapy, by increasing intratumoral drug uptake [8].”
BackgroundHistological and Molecular Evaluation of Patient-Derived Colorectal Cancer Explants
Uronis, J. M., Osada, T., McCall, S., Yang, X. Y., Mantyh, C., Morse, M. A., Lyerly, H. K., Clary, B. M., & Hsu, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038422 · Cited by 52
“In addition, recent reports suggest that tumor-stroma interactions not present in cell line-based xenografts may represent an integral component in oncogenic potential and tumor drug response [9,10].”
BackgroundHematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment
Xiong, Y., McDonald, L. T., Russell, D. L., Kelly, R. R., Wilson, K. R., Mehrotra, M., Soloff, A. C., & LaRue, A. C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i2.253 · Cited by 56
Kikuchi, H., Maishi, N., Annan, D. A., Alam, M. T., Dawood, R., Sato, M., Morimoto, M., Takeda, R., Ishizuka, K., Matsumoto, R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3791 · Cited by 55
“For example, the recruitment of bone marrow–derived immunosuppressive cells or secreting factors from cancer-associated fibroblasts may contribute to tumor progression and chemoresistance (11, 12).”
BackgroundA bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 53
Qiu, X., Zhang, F.-F., Geng, F., Liu, C., Xu, P., Lu, Z.-Z., Yu, B., Wu, H., Wu, J., Zhang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1827-4 · Cited by 50
“Even though FAPα can be found transiently overexpressed during wound healing, targeting this protein by vaccination did not impair wound healing, nor did it cause any discernible harmful reactions consistent with previous studies [12, 14, 34].”
BackgroundMethodResultInfluentialSchiarea, S., Solinas, G., Allavena, P., Scigliuolo, G. M., Bagnati, R., Fanelli, R., & Chiabrando, C. (2010) · Journal of Proteome Research · doi:10.1021/pr1001109 · Cited by 55
Zheng, J., & Hao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1333839 · Cited by 54
Huang, Z., Chen, J., Zhu, T., Li, J., Ng, H. Y., Zhou, Y., Gu, X., Xu, S., & Jia, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02533-1 · Cited by 66
“In preclinical models, an adeno-viral vaccine encoding FAP activated CD8 ⁺ T cells, significantly inhibiting both primary tumors and metastases in multidrug-resistant mouse models of colorectal and breast cancer [184].”
LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response
Zou, W., Zheng, H., He, T., Chang, J., Fu, Y., & Fan, W. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4216 · Cited by 53
Kaemmerer, E., Loessner, D., & Avery, V. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.030 · Cited by 56
Fibroblast Activation Protein Expression in Sarcomas
Crane, J. N., Graham, D. S., Mona, C. E., Nelson, S. D., Samiei, A., Dawson, D. W., Dry, S., Masri, M. G., Crompton, J. G., Benz, M., et al. (2023) · Sarcoma · doi:10.1155/2023/2480493 · Cited by 48
Metadata
- Authors
- Loeffler, M.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Loeffler, M.
- ORCID
- Loeffler, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1955-1962
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1481657
- OpenAlex
- W2002689409
- Cited by
- 633
- References
- 51
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 41 · 2023: 58 · 2022: 33 · 2021: 56 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 32 · 2016: 39 · 2015: 46 · 2014: 33 · 2013: 33 · 2012: 28
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (CA 83856, R01CA083856)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, oral DNA vaccine, type I collagen, tumor stroma, chemosensitization, multidrug resistance, colon cancer, breast cancer, metastasis, chemoimmunotherapy
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Female, Fibroblasts, Membrane Proteins, Mice, Inbred BALB C, Neoplasms, Endopeptidases, Recombinant Fusion Proteins, Serine Endopeptidases, Survival Rate, Gelatinases, CD8-Positive T-Lymphocytes, Vaccines, DNA, Cancer Vaccines, Collagen Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.